Thrivent Financial for Lutherans Cuts Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Thrivent Financial for Lutherans lessened its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,336 shares of the specialty pharmaceutical company’s stock after selling 283 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Jazz Pharmaceuticals were worth $1,765,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Corient Private Wealth LLC lifted its stake in Jazz Pharmaceuticals by 34.5% in the 4th quarter. Corient Private Wealth LLC now owns 10,857 shares of the specialty pharmaceutical company’s stock worth $1,335,000 after purchasing an additional 2,784 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in shares of Jazz Pharmaceuticals by 19.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,146 shares of the specialty pharmaceutical company’s stock worth $387,000 after buying an additional 502 shares in the last quarter. Globeflex Capital L P boosted its stake in Jazz Pharmaceuticals by 59.1% during the fourth quarter. Globeflex Capital L P now owns 8,073 shares of the specialty pharmaceutical company’s stock valued at $994,000 after buying an additional 3,000 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Jazz Pharmaceuticals by 501.4% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company’s stock valued at $13,800,000 after buying an additional 93,422 shares in the last quarter. Finally, Avantax Advisory Services Inc. bought a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $264,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $122.92 on Friday. The stock has a 50 day moving average price of $132.30 and a 200 day moving average price of $122.54. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market capitalization of $7.47 billion, a P/E ratio of 17.31, a P/E/G ratio of 1.04 and a beta of 0.44.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Morgan Stanley restated an “overweight” rating and issued a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $145.00 to $179.00 in a report on Friday, March 7th. JPMorgan Chase & Co. increased their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $187.71.

Insider Transactions at Jazz Pharmaceuticals

In other news, CMO Robert Iannone sold 2,403 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $138.41, for a total transaction of $332,599.23. Following the transaction, the chief marketing officer now directly owns 79,621 shares of the company’s stock, valued at approximately $11,020,342.61. This trade represents a 2.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Patricia Carr sold 1,140 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the completion of the sale, the chief accounting officer now owns 7,012 shares of the company’s stock, valued at $966,323.72. The trade was a 13.98 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,736 shares of company stock worth $4,022,825. 4.20% of the stock is currently owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.